Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03395704 · ClinicalTrials.gov registry record · Phase 2
A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis
A Phase 2 study, sponsored by La Jolla Pharmaceutical Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT03395704: Completed Phase 2 study, sponsored by La Jolla Pharmaceutical Company.
NCT03395704 is a Phase 2 study that has completed, run by La Jolla Pharmaceutical Company. The registered enrollment target is 70 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03395704, a Phase 2 study, has completed, sponsored by La Jolla Pharmaceutical Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
This study is a Phase 2 multicenter, randomized, placebo controlled, single-blind study. The primary objective of the study is to compare the effect of weekly dosing of LJPC-401 (synthetic human hepcidin) versus placebo on transferrin saturation (TSAT) in an adult hereditary hemochromatosis patient population.
Primary Outcome
Percentage change in transferrin saturation (TSAT) as measured by blood laboratory tests.
Interventions
- DRUG Placebo
- DRUG LJPC-401
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2017-11-29 |
| Est. Completion | 2019-10-28 |
| Phase | Phase 2 |
What the finished NCT03395704 record still lists
NCT03395704 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (47% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03395704 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03395704 about?
NCT03395704 is a clinical study titled "A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis". This study is a Phase 2 multicenter, randomized, placebo controlled, single-blind study. The primary objective of the study is to compare the effect of weekly dosing of LJPC-401 (synthetic human hepcidin) versus placebo on transferrin saturation (TSAT) in an adult hereditary hemochromatosis patient ...
What is the current status of trial NCT03395704?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2017-11-29. Estimated completion is 2019-10-28.
What interventions are being tested in trial NCT03395704?
The interventions under investigation include: Placebo (DRUG), LJPC-401 (DRUG).
Who is sponsoring clinical trial NCT03395704?
This trial is sponsored by La Jolla Pharmaceutical Company, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03395704's enrollment target sits among peer trials
70 937th of 2000 higher than 1,036 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI